First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 Evaluation of Cristal’s CliCr® and Intravacc’s OMV technology Bilthoven and Maastricht, the Netherlands, 6 January 2021 – Intravacc, a world leader in translational research and development of vaccines, and Cristal Therapeutics, a technology leader in enabling safer and more effective therapeutics, today announced a […]
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 Evaluation of Cristal’s CliCr® and Intravacc’s OMV technology Bilthoven and Maastricht, the Netherlands, 6 January 2021 – Intravacc, a world leader in translational research and development of vaccines, and Cristal Therapeutics, a technology leader in enabling safer and more effective therapeutics, today announced a […]
BIO Europe
October 26-29 2020 BIO-Europe Digital
Cristal Therapeutics announces a publication in ‘Chemical Science’ on CliCr® technology platform, comprising a new class of superior copper free click reagents for conjugation of small molecules, biologics, nanoparticles and other moieties
Flagship chemistry journal describes the development of TMTHSI (CliCr®) as a superior click reagent Cristal applies the CliCr® platform to the rational design of CriPec® nanomedicines, also enabling modular CriVac® vaccine product development CliCr® can be partnered or licensed as a stand-alone technology Cristal is actively seeking partners for CliCr® for a variety of applications Maastricht, The Netherlands, 29 September 2020 – Cristal Therapeutics, […]
Oncology Virtual Partnering
September 22-24 2020 Oncology Virtual Partnering Digital
BioPharm America
September 21-24 2020 BioPharm America Digital
Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform
Horizon 2020 INNOSUP grant allows the funding of a highly skilled and experienced researcher (Innovation Associate) to develop and implement state-of-art (bio)analytical methodologies for further understanding of the biological behaviour of CriPec® nanomedicines Maastricht, The Netherlands, 2nd July 2020 – Cristal Therapeutics, a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer […]
Cristal Therapeutics Publishes Positive Data on its CriPec® Nanomedicine Technology in Small
Small publication demonstrates that superior therapeutic profiles of CriPec® nanomedicines result from rational design Maastricht, The Netherlands, 11th May 2020 – Cristal Therapeutics, a Phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces the publication of a paper on its CriPec® nanomedicine technology […]
BIO-Europe 2019
November 11-13 BIO-Europe Hamburg, Germany
PODD
October 7-8 PODD Boston, USA
ESMO Annual Congress 2019
September 27 – October 1 ESMO Annual Congress 2019 Barcelona, Spain